Migraine with Aura disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MGR003 MIFTS: 51	Migraine with Aura Categories: Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Migraine with Aura

MalaCards integrated aliases for Migraine with Aura:

Name: Migraine with Aura ¹¹ ⁵ ⁴³ ¹⁴ ⁷¹ ³³

Migraine with Typical Aura ⁷¹

Acute Migraine with Aura ³³

Migraine Accompagnée ³³

Complicated Migraine ³³

Classical Migraine ³³

Classic Migraine ¹¹

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the nervous system

Episodic and paroxysmal disorders

Migraine

Migraine with aura [classical migraine]

ICD11: ³³

Diseases of the nervous system

Headache disorders

Migraine

Migraine with aura

External Ids:

Disease Ontology ¹¹ DOID:10024

ICD9CM ³⁴ 346.0

MeSH ⁴³ D020325

NCIt ⁴⁹ C117005

SNOMED-CT ⁶⁸ 155047002

ICD10 ³¹ G43.1

ICD11 ³³ 525744634

UMLS ⁷¹ C0154723 C1735856

Sources

Summaries for Migraine with Aura

Disease Ontology: ¹¹ A migraine characterized by migraine headache which is preceded or accompanied by a transient focal neurological phenomenon.

MalaCards based summary: Migraine with Aura, also known as migraine with typical aura, is related to migraine, familial hemiplegic, 1 and familial hemiplegic migraine, and has symptoms including headache An important gene associated with Migraine with Aura is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are Monoamine GPCRs and Synaptic vesicle pathway. The drugs Milnacipran and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and cortex, and related phenotypes are nervous system and normal

Sources

Related Diseases for Migraine with Aura

Diseases in the Migraine with Aura family:

Migraine with Aura 7

Migraine with Aura 9

Diseases related to Migraine with Aura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)

#	Related Disease	Score	Top Affiliating Genes
1	migraine, familial hemiplegic, 1	32.8	SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
2	familial hemiplegic migraine	32.7	SCN1A PRRT2 NOTCH3 KCNK18 CACNA1A ATP1A2
3	migraine, familial hemiplegic, 2	32.7	SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
4	migraine, familial hemiplegic, 3	32.7	SCN1A PRRT2 KCNK18 CACNA1A ATP1A2
5	familial or sporadic hemiplegic migraine	32.6	SCN1A PRRT2 CACNA1A ATP1A2
6	migraine with or without aura 1	32.4	SLC6A4 SCN1A PRRT2 NOTCH3 MTHFR MGR1
7	headache	32.1	SLC6A4 SCN1A CACNA1A ATP1A2
8	migraine without aura	31.9	SLC6A4 SCN1A NOTCH3 MTHFR KCNK18 FHL5
9	patent foramen ovale	31.5	SCN1A NOTCH3 MTHFR FLNA EDN1 CACNA1A
10	transient cerebral ischemia	31.4	NOTCH3 MTHFR ACE
11	atrial heart septal defect	31.1	MTHFR FLNA EDN1 ACE
12	vascular disease	31.1	SLC6A4 NOTCH3 MTHFR EDN1 ACE
13	hemiplegia	31.0	SCN1A EDN1 CACNA1A ATP1A2
14	early myoclonic encephalopathy	30.9	SCN1A PRRT2 CACNA1A
15	major depressive disorder	30.9	SLC6A4 NOTCH3 HTR2C HTR1D HTR1B DRD2
16	syncope	30.9	EDN1 DBH
17	alternating hemiplegia of childhood	30.7	SCN1A PRRT2 CACNA1A ATP1A2
18	epilepsy	30.7	SCN1A PRRT2 FLNA DBH CACNA1A ATP1A2
19	epilepsy, idiopathic generalized	30.6	SCN1A PRRT2 CACNA1A ATP1A2
20	tobacco addiction	30.6	SLC6A4 MTHFR DRD2 DBH
21	generalized anxiety disorder	30.6	SLC6A4 HTR2C HTR1B DRD2
22	eclampsia	30.6	MTHFR EDN1 ACE
23	panic disorder	30.6	SLC6A4 HTR2C HTR1B DRD2 ACE
24	mood disorder	30.6	SLC6A4 HTR2C HTR1B DRD2 DBH
25	pure autonomic failure	30.5	DBH ACE
26	epilepsy, myoclonic juvenile	30.5	SCN1A PRRT2 CACNA1A
27	anxiety	30.5	SLC6A4 HTR2C HTR1D HTR1B DRD2 ACE
28	orthostatic intolerance	30.5	FLNA DBH ACE
29	bipolar disorder	30.5	SLC6A4 MTHFR HTR2C HTR1B DRD2 DBH
30	vascular dementia	30.3	NOTCH3 MTHFR ACE
31	personality disorder	30.3	SLC6A4 HTR2C HTR1D HTR1B DRD2
32	migraine with aura 7	11.6
33	migraine with aura 9	11.5
34	epilepsy, familial temporal lobe, 4	11.5
35	migraine with or without aura 13	11.2
36	familiar or sporadic hemiplegic migraine	11.2
37	brain small vessel disease	10.5	NOTCH3 KCNK18
38	central nervous system origin vertigo	10.5	MTHFR CACNA1A
39	cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2	10.5	NOTCH3 CACNA1A ATP1A2
40	trigeminal neuralgia	10.5	SLC6A4 SCN1A CACNA1A
41	contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a	10.5
42	infancy electroclinical syndrome	10.5	SCN1A PRRT2 ATP1A2
43	episodic ataxia, type 5	10.5	CACNA1A ATP1A2
44	advanced sleep phase syndrome, familial, 2	10.5	PRRT2 KCNK18
45	childhood electroclinical syndrome	10.5	SCN1A PRRT2 CACNA1A
46	torticollis	10.5	PRRT2 DRD2 CACNA1A
47	intermittent explosive disorder	10.5	SLC6A4 HTR2C DRD2
48	autonomic nervous system disease	10.5	SCN1A DBH ACE
49	brain small vessel disease 1	10.5	NOTCH3 KCNK18 CACNA1A ATP1A2
50	paine syndrome	10.5	SLC6A4 SCN1A KCNK18

Comorbidity relations with Migraine with Aura via Phenotypic Disease Network (PDN):

Hypertension, Essential

Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with Aura:

Sources

Symptoms & Phenotypes for Migraine with Aura

UMLS symptoms related to Migraine with Aura:

headache

MGI Mouse Phenotypes related to Migraine with Aura:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.18	ATP1A2 CACNA1A DBH DRD2 EDN1 FLNA
2	normal	MP:0002873	10.1	ATP1A2 CACNA1A DBH DRD2 EDN1 FLNA
3	growth/size/body region	MP:0005378	10.1	ACE ATP1A2 CACNA1A DBH DRD2 EDN1
4	muscle	MP:0005369	9.97	ATP1A2 CACNA1A DRD2 EDN1 HTR1B HTR2C
5	endocrine/exocrine gland	MP:0005379	9.85	ACE CACNA1A DBH DRD2 EDN1 FHL5
6	behavior/neurological	MP:0005386	9.77	ACE ATP1A2 CACNA1A DBH DRD2 FLNA
7	reproductive system	MP:0005389	9.32	ACE CACNA1A DRD2 FHL5 FLNA HTR1B

Sources

Drugs & Therapeutics for Migraine with Aura

Drugs for Migraine with Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Milnacipran

Approved, Investigational

Phase 4

92623-85-3, 96847-54-0

11622909 65833 6917779

Norepinephrine

Approved

Phase 4

51-41-2

439260

Topiramate

Approved

Phase 4

97240-79-4

5284627

Metoclopramide

Approved, Investigational

Phase 4

364-62-5

4168

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Diclofenac

Approved, Vet_approved

Phase 4

15307-86-5, 15307-79-6

3033

Almotriptan

Approved, Investigational

Phase 4

181183-52-8, 154323-57-6

123606

Psychotropic Drugs

Phase 4

Antidepressive Agents

Phase 4

Serotonin and Noradrenaline Reuptake Inhibitors

Phase 4

Hypoglycemic Agents

Phase 4

Dopamine Antagonists

Phase 4

Antiemetics

Phase 4

Gastrointestinal Agents

Phase 4

Ketorolac Tromethamine

Phase 4

Serotonin Receptor Agonists

Phase 4

Cyclooxygenase Inhibitors

Phase 4

Serotonin

Investigational, Nutraceutical

Phase 4

50-67-9

5202

Caffeine

Approved

Phase 3

58-08-2

2519

Eletriptan

Approved, Investigational

Phase 3

143322-58-1

77993

Rizatriptan

Approved

Phase 3

145202-66-0, 144034-80-0

5078

Sumatriptan

Approved, Investigational

Phase 3

103628-46-2

5358

Angiotensin II

Approved, Investigational

Phase 2, Phase 3

68521-88-0, 11128-99-7, 4474-91-3

172198

Candesartan cilexetil

Approved

Phase 2, Phase 3

145040-37-5

Propranolol

Approved, Investigational

Phase 2, Phase 3

318-98-9, 525-66-6

62882 4946

Histamine

Approved, Investigational

Phase 3

51-45-6

774

Diphenhydramine

Approved, Investigational

Phase 3

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

Phase 3

60-87-7

4927

Ketoprofen

Approved, Vet_approved

Phase 3

22071-15-4

3825

Dopamine

Approved

Phase 3

62-31-7, 51-61-6

681

Ergotamine

Approved

Phase 3

113-15-5

8223

Dihydroergotamine

Approved, Investigational

Phase 3

6190-39-2, 511-12-6

10531

Clonidine

Approved

Phase 3

4205-91-8, 4205-90-7

2803 20179

Tizanidine

Approved, Investigational

Phase 3

51322-75-9

5487

Candesartan

Experimental

Phase 2, Phase 3

139481-59-7

2541

Vasodilator Agents

Phase 3

Central Nervous System Stimulants

Phase 3

Phosphodiesterase Inhibitors

Phase 3

Serotonin 5-HT1 Receptor Agonists

Phase 3

Adrenergic beta-Antagonists

Phase 2, Phase 3

Adrenergic Antagonists

Phase 2, Phase 3

Anti-Arrhythmia Agents

Phase 2, Phase 3

Angiotensinogen

Phase 2, Phase 3

16133225

Angiotensin Receptor Antagonists

Phase 2, Phase 3

Angiotensin II Type 1 Receptor Blockers

Phase 2, Phase 3

Giapreza

Phase 2, Phase 3

Anesthetics, Local

Phase 3

Anesthetics

Phase 3

Anti-Allergic Agents

Phase 3

Histamine phosphate

Phase 3

51-74-1

134614

Interventional clinical trials:

(show top 50) (show all 84)

#	Name	Status	NCT ID	Phase	Drugs
1	Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine.	Unknown status	NCT01319825	Phase 4	milnacipran
2	Interest of the T2 * Sequence in MRI for the Diagnosis of Migraine Aura in the Acute Phase.	Completed	NCT03689361	Phase 4
3	Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department	Completed	NCT01596166	Phase 4	Ketorolac Tromethamine;Metoclopramide
4	TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study	Completed	NCT00212810	Phase 4	Topiramate
5	Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate)	Completed	NCT00210496	Phase 4	topiramate; almotriptan malate
6	A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine (ATOM)	Recruiting	NCT05211154	Phase 4	Diclofenac Potassium 50Mg/Pkt Oral Pwdr;Rimegepant 75 MG
7	A Randomized, Parallel-Group, Single-Attack, Open-Label Study to Evaluate the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine (ATOM).	Recruiting	NCT05214001	Phase 4	Almotriptan 12.5 Mg Oral Tablet;Ubrogepant 50Mg Tab
8	Phase III Randomized Double-Blind Parallel Group Sham-Controlled Study Evaluating the Efficacy and Safety of Non-invasive Non-repetitive Transcranial Magnetic Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache	Completed	NCT00449540	Phase 3
9	A Multicentre, Dose Optimisation Study to Assess the Consistency of Efficacy of Eletriptan for the Treatment of Migraine (With and Without Aura)	Completed	NCT01859481	Phase 3	Placebo;Eletriptan HBr 40 mg;Eletriptan HBr 80 mg
10	Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache	Completed	NCT00471952	Phase 3	Maxalt 10mg MLT plus Caffeine 75mg;Maxalt 10mg MLT plus Placebo;Placebo + Placebo
11	EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine	Completed	NCT03901482	Phase 3	Dihydroergotamine;Placebos
12	Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study	Completed	NCT00884663	Phase 2, Phase 3	Candesartan;propranolol;placebo
13	A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine	Completed	NCT04940390	Phase 3	Dihydroergotamine;Placebo
14	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine	Completed	NCT00231595	Phase 3	topiramate
15	A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine	Completed	NCT00334178	Phase 3	Laxymig ER (drug)
16	A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine	Completed	NCT00236561	Phase 3	topiramate, propranolol
17	A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine	Completed	NCT00236509	Phase 3	topiramate
18	A Double-Blind Dose Comparison Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine	Completed	NCT00131443	Phase 2, Phase 3	Topiramate
19	Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial	Completed	NCT01814189	Phase 3	Sumatriptan+Promethazine (SPr)
20	Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room	Recruiting	NCT04726592	Phase 3	Clorazepate Dipotassium;Placebo;Ketoprofen;Metoclopramide
21	An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine	Active, not recruiting	NCT04406649	Phase 3	Dihydroergotamine
22	Safety and Efficacy of Oral Tizanidine Hydrochloride in Preventing Migraine Attacks in Adult Migraine Patients: a Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Study	Not yet recruiting	NCT05484349	Phase 3	Tizanidine Hydrochloride;Tizanidine Hydrochloride Placebo
23	A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety, And Tolerability Of Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine	Not yet recruiting	NCT05416476	Phase 3	Anisodine Hydrobromide;Anisodine Hydrobromide placebo
24	Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches.	Unknown status	NCT03220113	Phase 1, Phase 2
25	Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura	Unknown status	NCT04063540	Phase 2	Amiloride;Placebos
26	A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura	Unknown status	NCT00877838	Phase 2	NXN-188;Placebo
27	Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study	Unknown status	NCT00285402	Phase 2	AST-726 Low dose;AST-726 High dose;AST-726 Placebo
28	Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension	Completed	NCT00534560	Phase 2	Tonabersat;Placebo
29	A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache	Completed	NCT00123201	Phase 2	Dronabinol MDI
30	A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache With Aura	Completed	NCT00920686	Phase 2	NXN-188;placebo;sumatriptan succinate
31	A Single Centre, Double-blind, Randomised, Placebo Controlled Crossover Study to Evaluate the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine in Patients Presenting With Migraine With Aura	Completed	NCT00332007	Phase 2	Tonabersat;Placebo
32	Multi-centre, Parallel Group, Double-blind, Placebo Controlled Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache	Completed	NCT00311662	Phase 2	Tonabersat;Placebo
33	An Open-Label Study of Topiramate in Pediatric Subjects With Basilar/Hemiplegic Migraine	Completed	NCT00158002	Phase 2	Topiramate
34	Effects of DFN-15 on Migraine With Allodynia	Completed	NCT03472378	Phase 2	DFN-15
35	A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine	Terminated	NCT00739024	Phase 2	Ramelteon;Placebo
36	Percutaneous Closure of Patent Foramen Ovale In Migraine With Aura - A Randomized Prospective Study (Prima Trial)	Terminated	NCT00505570	Phase 2
37	A Randomized, Open-Label, Crossover Study to Evaluate the PK, Bioavailability, Dose Proportionality, Safety, and Tolerability of Single Doses of STS101, DHE Mesylate IM Injection and DHE Mesylate Nasal Spray in Healthy Adult Subjects	Completed	NCT03874832	Phase 1	Dihydroergotamine
38	A Randomized, Open-Label, 5-Period Crossover Study to Evaluate the PK, Bioavailability, Safety, and Tolerability of Single Doses of STS101, DHE IM Injection and DHE Nasal Spray in Healthy Adult Subjects	Completed	NCT05337254	Phase 1	Dihydroergotamine
39	MR-Angiografi (MRA) og MR-Spektroskopi (MRS) Hos Raske forsøgspersoner og Patienter Med migræne Uden Aura Provokeret Med Calcitonin Gen-relateret Peptid (CGRP) og Sildenafil	Unknown status	NCT03143465		Calcitonin Gene-Related Peptide;Sildenafil;Placebo
40	A Parallel Two Arm, Double Blinded Placebo Study, Examining the Efficacy of Sumatriptan With Naprosyn in the Treatment of Migraine With Aura	Unknown status	NCT00893594		sumatriptan with naprosyn;placebo
41	The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients	Unknown status	NCT04452929		Erenumab;Placebo;Calcitonin gene-related peptide;Cilostazol
42	Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI	Unknown status	NCT02202486
43	Functional MRI and MRA in Migraine With Aura	Unknown status	NCT01388894
44	Investigations of the Endogenous Vasoconstrictor and Neuromodulator Peptide Endothelin-1 as a Potential Trigger of Migraine Aura	Unknown status	NCT02906085		Endothelin-1;Placebo
45	CGRP-induced Headache in Patients With Familial Hemiplegic Migraine, Migraine With Aura and Healthy Controls	Completed	NCT00687947		CGRP
46	Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura : a MRI and Transcranial Doppler.	Completed	NCT02708797
47	Impact of tDCS on Cerebral Autoregulation	Completed	NCT01865604
48	IndoProCaf (Difmetre®) Effervescent Tablets Effectiveness in Acute Treatment of Primary Headaches (Migraine and/or Episodic Tension-type Headache) and Patients' Satisfaction With the Treatment in Routine Clinical Practice in Ukraine and Kazakhstan	Completed	NCT02115269
49	Women With Migraine With Aura Neuroimaging (WOMAN) Study: A Population-based Study of Danish Twins	Completed	NCT02047695
50	Study of Migraine With Aura Inducing Characteristics and Effects on the Cerebral Arteries by Hypoxia in a Humane Experimental Migraine Model	Completed	NCT01896167

Search NIH Clinical Center for Migraine with Aura

Cochrane evidence based reviews: migraine with aura

Sources

Genetic Tests for Migraine with Aura

Sources

Anatomical Context for Migraine with Aura

Organs/tissues related to Migraine with Aura:

MalaCards : Brain, Endothelial, Cortex, Occipital Lobe, Trigeminal Ganglion, Heart, Caudate Nucleus

Sources

Publications for Migraine with Aura

Articles related to Migraine with Aura:

(show top 50) (show all 2947)

#	Title	Authors	PMID	Year
1	Whole-genome sequencing of patients with rare diseases in a national health system. ⁵	Turro E...Ouwehand WH	32581362	2020
2	Stroke and stroke risk factors in women of reproductive age with a history of metabolic or bariatric surgery. ⁶²	Christopher KM...Linares G	36206629	2022
3	Vestibular Function and Clinical Presentation of Dizziness: Are They Similar in Patients With Different Types of Migraine? ⁶²	Faim AE...Carneiro CG	36198653	2022
4	Non-aura visual disturbance with high visual aura rating scale scores has stronger association with migraine chronification than typical aura. ⁶²	Tsao YC...Chen SP	36068697	2022
5	Evaluating the correlation between migraine and subclinical atherosclerosis. ⁶²	Esmaeili S...Taghi Joghataei M	36242871	2022
6	Lack of Habituation in Migraine Patients Based on High-Density EEG Analysis Using the Steady State of Visual Evoked Potential. ⁶²	Abbas Abdulhussein M...An X	36421543	2022
7	MRI findings on a paediatric complicated migraine: left hemispheric hypoperfusion and deoxygenation. ⁶²	Arredondo Montero J...Elduayen Aldaz B	36385008	2022
8	An Association Study of ESR1-XbaI and PvuII Gene Polymorphism in Migraine Susceptibility in the Jammu Region. ⁶²	Kumar S...Kumar P	36436502	2022
9	Migraine Type-Dependent Patterns of Brain Activation After Facial and Intranasal Trigeminal Stimulation. ⁶²	Haehner A...Iannilli E	36370239	2022
10	Study of variants in genes implicated in rare familial migraine syndromes and their association with migraine in 200,000 exome-sequenced UK Biobank participants. ⁶²	Markel KA...Curtis D	36044383	2022
11	Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial. ⁶²	Takeshima T...Tatsuoka Y	36138260	2022
12	Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine. ⁶²	Iannone LF...Chiarugi A	35775208	2022
13	Development of a cluster-like headache after a stent-assisted implantation of an endovascular WEB device. ⁶²	Meyer T...Werner CJ	36379623	2022
14	Visual snow: A systematic review and a case series. ⁶²	Sampatakakis SN...Mitsikostas DD	35945691	2022
15	Stroke-prone salt-sensitive spontaneously hypertensive rats show higher susceptibility to spreading depolarization (SD) and altered hemodynamic responses to SD. ⁶²	Kang EJ...Dreier JP	36329390	2022
16	Management and behavior-modifying recommendation effects in childhood headache. ⁶²	Gungor M...Karagoz YS	36326638	2022
17	E. H. Sieveking and his cephalalgia epileptica. ⁶²	Eadie MJ	35724331	2022
18	A cross-sectional study on the association between Helicobacter pylori infection and headache. ⁶²	Cavestro C...Rota E	35643992	2022
19	Clinical application of brain perfusion imaging in detecting stroke mimics: A review. ⁶²	Khalili N...Yedavalli V	36207276	2022
20	Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL): A Rare Cause of Transient Ischemic Attack. ⁶²	Ashraf S...Khaja M	36465750	2022
21	Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study. ⁶²	Fu T...Wu X	36195842	2022
22	Levetiracetam in the prophylactic treatment of episodic migraine: A prospective open label study. ⁶²	Evers S...Marziniak M	35633027	2022
23	Meta-analytical evidence of functional and structural abnormalities associated with pain processing in migraine patients: An activation likelihood estimation. ⁶²	Al Qawasmeh M...El Salem K	36316871	2022
24	Migraine and Current Pharmacologic Management. ⁶²	Okobi OE...Evbayekha EO	36337819	2022
25	A systematic review and meta-analysis of voxel-based morphometric studies of migraine. ⁶²	Zhang X...Zeng F	36098838	2022
26	The headache and aura-inducing effects of sildenafil in patients with migraine with aura. ⁶²	Butt JH...Kruuse C	35332812	2022
27	Impact of Greater Occipital Nerve Block on Photophobia Levels in Migraine Patients. ⁶²	Membrilla JA...Diaz de Teran J	35421036	2022
28	2022 Taiwan Guidelines for Preventive Treatment of Migraine. ⁶²	Wu JW...Treatment Guideline Subcommittee of the Taiwan Headache Society	36089629	2022
29	P3 latency as a biomarker for the complexity of migraine with aura: Event-related potential study. ⁶²	Petrusic I...Savic AM	35332814	2022
30	PARACENTRAL ACUTE MIDDLE MACULOPATHY IN A PATIENT WITH FREQUENT MIGRAINE WITH AURA: A CASE REPORT. ⁶²	Dasari VR...Gratton SM	36001683	2022
31	Elderly CADASIL patients with intact neurological status. ⁶²	Zhang R...Chabriat H	36221938	2022
32	Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men. ⁶²	Chiang CC...Noseworthy PA	35676887	2022
33	Physical activity pattern and migraine according to aura symptoms in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) cohort: A cross-sectional study. ⁶²	Oliveira AB...Goulart AC	36017980	2022
34	Prevalence Rates of Primary Headache Disorders and Evaluation and Treatment Patterns Among Korean Neurologists. ⁶²	Kim BK...Cho SJ	36062775	2022
35	Evidence-Based Contraception: Common Questions and Answers. ⁶²	Paradise SL...Klein DA	36126006	2022
36	Interneuronal dynamics facilitate the initiation of spike block in cortical microcircuits. ⁶²	Stein W...Harris AL	35441302	2022
37	The Epidemiology of Primary Headache Disorders. ⁶²	Kopel D...Gottschalk C	36104164	2022
38	Headache in Children and Adolescents: The Association between Screen Time and Headache within a Clinical Headache Population. ⁶²	Lund J...Debes NMM	34905787	2022
39	The Modifying of Functional Connectivity Induced by Peripheral Nerve Field Stimulation using Electroacupuncture for Migraine: A Prospective Clinical Study. ⁶²	Ishiyama S...Ishikawa E	35312785	2022
40	Insular functional connectivity in migraine with aura. ⁶²	Gollion C...Peran P	35982396	2022
41	Mutation screening and association analysis of NOTCH3 p.R544C in patients with migraine with or without aura. ⁶²	Wang YF...Wang SJ	35302383	2022
42	Cerebrovascular function in tension-type headache and migraine with or without aura: Transcranial Doppler study. ⁶²	Khedr EM...Zaki AF	35982093	2022
43	Evaluation of retinal vessel and perfusion density in migraine patients by optical coherence tomography angiography. ⁶²	He N...Lv Z	35961536	2022
44	Ocular Migraine With Amaurosis Fugax of the Left Eye: A Case Report. ⁶²	Tazin F...Go CC	36158378	2022
45	Association between migraine and risk of stroke: a systematic review and meta-analysis. ⁶²	Zhang S...Shi T	35451664	2022
46	Migraine-Associated Common Genetic Variants Confer Greater Risk of Posterior vs. Anterior Circulation Ischemic Stroke☆. ⁶²	Frid P...Lindgren A	35576861	2022
47	Interictal plasma endothelin-1 levels do not change in individuals with episodic and chronic migraine. ⁶²	Kim J...Chu MK	35166151	2022
48	Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks. ⁶²	Coppola G...Sarchielli P	35820799	2022
49	Gradually shifting clinical phenomics in migraine spectrum: a cross-sectional, multicenter study of 5438 patients. ⁶²	Ran Y...Yu S	35883029	2022
50	Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign. ⁶²	Hirtz C...Viguier A	35301873	2022

Sources

Genes for Migraine with Aura

Genes related to Migraine with Aura (4 elite genes):

(show top 50) (show all 59)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	NOTCH3	Notch Receptor 3	Protein Coding	441.42	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	32581362
2	FLNA	Filamin A	Protein Coding	400	Pathogenic ⁵
3	MGR7	Migraine With Aura, Susceptibility To, 7	Genetic Locus	67.97	MalaCards inferred ³⁹ GeneCards inferred via : Publications Gene name (show sections)
4	MGR9	Migraine With Aura, Susceptibility To, 9	Genetic Locus	58.56	MalaCards inferred ³⁹ GeneCards inferred via : Gene name (show sections)
5	KCNK18	Potassium Two Pore Domain Channel Subfamily K Member 18	Protein Coding	36.25	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)
6	ATP1A2	ATPase Na+/K+ Transporting Subunit Alpha 2	Protein Coding	29.65	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
7	CACNA1A	Calcium Voltage-Gated Channel Subunit Alpha1 A	Protein Coding	29.63	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
8	MGR1	Migraine With Aura, Susceptibility To	Genetic Locus	18.24	GeneCards inferred via : Publications Gene name (show sections)
9	SCN1A	Sodium Voltage-Gated Channel Alpha Subunit 1	Protein Coding	17.96	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
10	PRRT2	Proline Rich Transmembrane Protein 2	Protein Coding	16.13	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	16.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	HTR1B	5-Hydroxytryptamine Receptor 1B	Protein Coding	15.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	HTR1D	5-Hydroxytryptamine Receptor 1D	Protein Coding	14.63	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	14.53	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	ACE	Angiotensin I Converting Enzyme	Protein Coding	14.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	HTR2C	5-Hydroxytryptamine Receptor 2C	Protein Coding	13.77	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	DRD2	Dopamine Receptor D2	Protein Coding	13.74	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	DBH	Dopamine Beta-Hydroxylase	Protein Coding	13.65	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	EDN1	Endothelin 1	Protein Coding	13.4	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	FHL5	Four And A Half LIM Domains 5	Protein Coding	13.36	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	HTR2A	5-Hydroxytryptamine Receptor 2A	Protein Coding	13.16	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	SLC6A3	Solute Carrier Family 6 Member 3	Protein Coding	13.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	ESR1	Estrogen Receptor 1	Protein Coding	13.1	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	F2	Coagulation Factor II, Thrombin	Protein Coding	13.07	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	NOS3	Nitric Oxide Synthase 3	Protein Coding	13	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	VIP	Vasoactive Intestinal Peptide	Protein Coding	12.95	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	SLC2A1	Solute Carrier Family 2 Member 1	Protein Coding	12.8	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	IL6	Interleukin 6	Protein Coding	12.75	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	OPRM1	Opioid Receptor Mu 1	Protein Coding	12.66	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	EDNRA	Endothelin Receptor Type A	Protein Coding	12.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	INSR	Insulin Receptor	Protein Coding	12.31	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
32	MTRR	5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase	Protein Coding	12.25	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
33	MTR	5-Methyltetrahydrofolate-Homocysteine Methyltransferase	Protein Coding	12.06	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
34	EDNRB	Endothelin Receptor Type B	Protein Coding	12.02	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	ADORA2A	Adenosine A2a Receptor	Protein Coding	11.99	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	NPFF	Neuropeptide FF-Amide Peptide Precursor	Protein Coding	11.84	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	SPTAN1	Spectrin Alpha, Non-Erythrocytic 1	Protein Coding	11.67	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	GABRA5	Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5	Protein Coding	11.52	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	SOD2	Superoxide Dismutase 2	Protein Coding	11.24	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
40	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	10.87	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
41	LOC110806262	Solute Carrier Family 6 Member 4 Gene Promoter	Functional Element	8.73	GeneCards inferred via : Publications (show sections)
42	ETL4	Epilepsy, Occipitotemporal Lobe, And Migraine With Aura	Genetic Locus	8.56	GeneCards inferred via : Gene name (show sections)
43	F5	Coagulation Factor V	Protein Coding	8.35	GeneCards inferred via : Publications (show sections)
44	MGR5	Migraine With Or Without Aura, Susceptibility To, 5	Genetic Locus	7.94	GeneCards inferred via : Publications (show sections)
45	MMP2	Matrix Metallopeptidase 2	Protein Coding	7.94	GeneCards inferred via : Publications (show sections)
46	CALCA	Calcitonin Related Polypeptide Alpha	Protein Coding	7.37	DISEASES inferred ¹⁴
47	ATP1A3	ATPase Na+/K+ Transporting Subunit Alpha 3	Protein Coding	7.22	DISEASES inferred ¹⁴
48	CACNA1B	Calcium Voltage-Gated Channel Subunit Alpha1 B	Protein Coding	6.7	DISEASES inferred ¹⁴
49	TAC1	Tachykinin Precursor 1	Protein Coding	6.66	DISEASES inferred ¹⁴
50	TRPM8	Transient Receptor Potential Cation Channel Subfamily M Member 8	Protein Coding	6.65	DISEASES inferred ¹⁴

Sources

Variations for Migraine with Aura

ClinVar genetic disease variations for Migraine with Aura:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	NOTCH3	NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg)	SNV	Pathogenic	812745	rs1555729455	GRCh37: 19:15302816-15302816 GRCh38: 19:15192005-15192005
2	overlap with 2 genes	GRCh37/hg19 Xq28(chrX:153588672-153609996)	CN GAIN	Pathogenic	523301		GRCh37: X:153588672-153609996 GRCh38:
3	FLNA	GRCh37/hg19 Xq28(chrX:153575976-153586768)	CN LOSS	Pathogenic	523300		GRCh37: X:153575976-153586768 GRCh38:
4	NOTCH3	NM_000435.3(NOTCH3):c.1162T>C (p.Cys388Arg)	SNV	Likely Pathogenic	812743	rs1599391938	GRCh37: 19:15300114-15300114 GRCh38: 19:15189303-15189303
5	NOTCH3	NM_000435.3(NOTCH3):c.1136G>C (p.Cys379Ser)	SNV	Likely Pathogenic	812744	rs1599391986	GRCh37: 19:15300140-15300140 GRCh38: 19:15189329-15189329
6	DGUOK	NM_080916.3(DGUOK):c.278G>A (p.Gly93Glu)	SNV	Uncertain Significance	523553	rs1553403624	GRCh37: 2:74173868-74173868 GRCh38: 2:73946741-73946741
7	DGUOK	NM_080916.3(DGUOK):c.65C>T (p.Pro22Leu)	SNV	Uncertain Significance	523554	rs757962437	GRCh37: 2:74154102-74154102 GRCh38: 2:73926975-73926975

Sources

Expression for Migraine with Aura

Search GEO for disease gene expression data for Migraine with Aura.

Sources

Pathways for Migraine with Aura

Pathways related to Migraine with Aura according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Monoamine GPCRs ⁷⁴ Show member pathways Adrenaline signalling through Alpha-2 adrenergic receptor ⁶⁶ Adrenoceptors ⁶⁶ Amine ligand-binding receptors ⁶⁶ Histamine receptors ⁶⁶ Muscarinic acetylcholine receptors ⁶⁶ Serotonin receptors ⁶⁶	11.49	HTR2C HTR1D HTR1B DRD2
2	Synaptic vesicle pathway ⁷⁴	11.14	SLC6A4 CACNA1A ATP1A2
3	Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics ⁶⁰	10.7	SLC6A4 HTR2C HTR1D HTR1B
4	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	10.62	HTR2C DRD2
5	Methylphenidate Pathway, Pharmacodynamics ⁶⁰ Show member pathways Dopamine receptors ⁶⁶	10.29	SLC6A4 HTR1B DRD2 DBH

Sources

GO Terms for Migraine with Aura

Cellular components related to Migraine with Aura according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane	GO:0016021	10.5	ACE ATP1A2 CACNA1A DBH DRD2 HTR1B
2	membrane	GO:0016020	10.5	ACE ATP1A2 CACNA1A DBH DRD2 HTR1B
3	plasma membrane	GO:0005886	10.43	SLC6A4 KCNK18 HTR2C HTR1D HTR1B DRD2
4	plasma membrane	GO:0005887	10.43	SLC6A4 KCNK18 HTR2C HTR1D HTR1B DRD2
5	G protein-coupled serotonin receptor complex	GO:0098666	9.67	HTR2C HTR1B
6	presynaptic membrane	GO:0042734	9.65	SLC6A4 PRRT2 HTR1B DRD2
7	synapse	GO:0045202	9.5	SLC6A4 PRRT2 MTHFR HTR2C HTR1D DRD2
8	serotonergic synapse	GO:0099154	9.46	HTR1B SLC6A4
9	obsolete integral component of presynaptic membrane	GO:0099056	9.26	SLC6A4 PRRT2 HTR1B DRD2

Biological processes related to Migraine with Aura according to GeneCards Suite gene sharing:

(show all 23)

#	Name	GO ID	Score	Top Affiliating Genes
1	chemical synaptic transmission	GO:0007268	10.13	CACNA1A DBH HTR1B HTR1D HTR2C
2	response to xenobiotic stimulus	GO:0009410	10.11	SLC6A4 MTHFR EDN1 DRD2 ACE
3	G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	GO:0007187	10.08	HTR2C HTR1D HTR1B
4	adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	GO:0007193	10.03	EDN1 HTR1B HTR1D
5	visual learning	GO:0008542	10	ATP1A2 DBH DRD2
6	release of sequestered calcium ion into cytosol	GO:0051209	9.99	HTR2C FLNA DRD2
7	response to nicotine	GO:0035094	9.95	EDN1 DRD2 ATP1A2
8	negative regulation of synaptic transmission, glutamatergic	GO:0051967	9.91	HTR1B DRD2
9	regulation of behavior	GO:0050795	9.89	HTR1D HTR1B
10	negative regulation of cytosolic calcium ion concentration	GO:0051481	9.88	DRD2 ATP1A2
11	behavioral response to ethanol	GO:0048149	9.88	DRD2 DBH
12	blood vessel remodeling	GO:0001974	9.88	FLNA DBH ACE
13	drinking behavior	GO:0042756	9.87	HTR1B DRD2
14	adenylate cyclase-inhibiting serotonin receptor signaling pathway	GO:0007198	9.84	HTR1D HTR1B
15	adenylate cyclase-inhibiting dopamine receptor signaling pathway	GO:0007195	9.8	FLNA DRD2
16	response to amphetamine	GO:0001975	9.8	DBH DRD2 EDN1
17	positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway	GO:0051482	9.73	DRD2 EDN1 HTR2C
18	feeding behavior	GO:0007631	9.67	HTR2C HTR1B DRD2
19	regulation of vasoconstriction	GO:0019229	9.63	EDN1 ATP1A2 ACE
20	regulation of biological quality	GO:0065008	9.61	EDN1 DRD2
21	response to hypoxia	GO:0001666	9.61	SLC6A4 MTHFR EDN1 DRD2 ACE
22	behavior	GO:0007610	9.55	HTR2C HTR1B
23	vasoconstriction	GO:0042310	9.4	SLC6A4 HTR1D HTR1B EDN1 DBH ACE

Molecular functions related to Migraine with Aura according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	G protein-coupled serotonin receptor activity	GO:0004993	9.63	HTR2C HTR1D HTR1B
2	heterocyclic compound binding	GO:1901363	9.35	HTR1B DRD2 ACE
3	serotonin binding	GO:0051378	9.23	SLC6A4 HTR2C HTR1D HTR1B